Tirzepatide 10mg

Research applications

• Dual GIP/GLP-1 receptor binding and signalling studies
• Rodent models of glucose homeostasis and insulin secretion
• Comparative incretin-pathway pharmacology research
• Body-composition research in preclinical models

What the literature reports on tirzepatide

Tirzepatide's structure combines a modified GIP backbone with GLP-1 receptor activity, engineered through targeted amino acid substitutions including alpha-aminoisobutyric acid (Aib) residues that confer resistance to DPP-4 enzymatic degradation. This design is documented extensively in the pharmacology and medicinal chemistry literature describing incretin-based receptor agonists.

Receptor pharmacology research

In vitro receptor-binding studies have characterised tirzepatide's affinity and activity at both the GIP and GLP-1 receptors, reporting a distinct pharmacological profile compared with single-receptor agonists. This research has informed structural biology studies examining how dual-agonist peptides interact with incretin receptor binding pockets.

Metabolic research in animal models

Rodent and non-human primate studies have reported changes in glucose tolerance, insulin secretion dynamics and body weight parameters following tirzepatide administration, with findings generally interpreted in the context of combined incretin-receptor engagement. Comparative studies against selective GLP-1 receptor agonists have been used to isolate the specific contribution of GIP receptor co-agonism to the observed metabolic effects.

Half-life extension chemistry

The fatty diacid-linker conjugation strategy used in tirzepatide is itself a subject of pharmacokinetic research, with studies examining how albumin binding through this moiety extends circulating half-life relative to unmodified incretin peptides. This chemistry is shared conceptually with other long-acting peptide classes studied in metabolic research.

Comparative research against other incretin peptides

Research groups have used tirzepatide as a comparator compound alongside single-receptor GLP-1 agonists and other dual- or triple-receptor agonists, including retatrutide, to characterise how the number and combination of engaged incretin receptors relates to the magnitude and durability of metabolic effects observed in animal models. This comparative pharmacology forms a substantial part of the contemporary incretin-receptor research literature.

Species and model considerations

Because incretin receptor pharmacology can differ between rodent and primate species, researchers studying tirzepatide have reported the importance of selecting appropriate animal models when interpreting cross-species pharmacodynamic data, a methodological consideration documented across multiple independent research programmes examining GIP/GLP-1 receptor biology.

Laboratory handling

Tirzepatide is supplied as a lyophilised powder and should be stored at -20°C, protected from light and moisture, until reconstitution. As with other large modified peptides, reconstitution should introduce the diluent gently along the vial wall to avoid foaming or mechanical disruption of the peptide structure.

• Lyophilised powder: store at -20°C, protected from light, until reconstitution.
• Reconstitution: introduce diluent slowly along the vial wall; avoid vigorous shaking or foaming.
• Post-reconstitution: 2-8°C for short-term laboratory use; avoid repeated freeze-thaw cycles.
• Each batch ships with a certificate of analysis confirming ≥99% purity by HPLC and identity by mass spectrometry.

See the peptide reconstitution and storage guide for a full protocol reference. This product is intended for laboratory research use only.